With 99.79 million shares changed hands, the volume of the stock remained lighter than its average volume of 144.12 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $0.0666 whereas the lowest price it dropped to was $0.0575. The 52-week range on NCNA shows that it touched its highest point at $10.79 and its lowest point at $0.03 during that stretch. It currently has a 1-year price target of $23.75. Beta for the stock currently stands at 1.44.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NCNA was down-trending over the past week, with a drop of -33.15%, but this was up by 71.39% over a month. Three-month performance dropped to -93.07% while six-month performance fell -95.45%. The stock lost -94.92% in the past year, while it has lost -97.79% so far this year.
Float and Shares Shorts:
At present, 6.06 million NCNA shares are outstanding with a float of 5.70 million shares on hand for trading. On 2025-06-13, short shares totaled 4.61 million, which was 7607.000000000001 higher than short shares on 1747267200. In addition to Mr. Hugh Stephen Griffith as the firm’s Founder, CEO & Executive Director, Mr. David Harrison serves as its Head of Translational Medicine & Studies.
Institutional Ownership:
Through their ownership of 0.00125 of NCNA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, NCNA reported revenue of $0.0 and operating income of -$2792000.0. The EBITDA in the recently reported quarter was -$2666000.0 and diluted EPS was -$0.5.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NCNA since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.36547 being high and -$0.43795 being low. For NCNA, this leads to a yearly average estimate of -$0.4.
